Human leukocyte antigen class II molecules presenting New York esophageal squamous cell carcinoma 1 peptides (HLA-II/NY-ESO-1)

The HLA class II molecules on dendritic cells presenting NY-ESO-1 peptides constitute a specialized antigen-presenting complex vital for initiating CD4+ T cell-mediated anti-tumor immunity. NY-ESO-1 (New York esophageal squamous cell carcinoma 1) is a prominent cancer-testis antigen (CTA) that is aberrantly expressed in numerous cancers, including melanoma and synovial sarcoma, while remaining silent in normal adult tissues except for the testis [PMID: 9034906]. Dendritic cells (DCs) serve as professional antigen-presenting cells that internalize NY-ESO-1, process it into immunogenic peptides, and display these on their surface via Human Leukocyte Antigen (HLA) class II molecules [PMID: 15155834]. This presentation is recognized by the T-cell receptors (TCRs) of CD4+ T helper cells, which subsequently secrete cytokines like IFN-gamma and IL-2 to support the activation and expansion of cytotoxic CD8+ T cells [PMID: 21148347]. Therapeutic interventions targeting this complex include dendritic cell vaccines, recombinant viral vectors like LV305, and TCR-engineered T cell therapies designed to recognize specific NY-ESO-1/HLA-II combinations [PMID: 30635439, PMID: 27524443]. By leveraging the HLA class II pathway, these therapies aim to provide sustained T cell help and overcome the immunosuppressive barriers within the tumor microenvironment.

Other names

NY-ESO-1/HLA-II complexMHC class II-restricted NY-ESO-1 antigenNY-ESO-1 peptide-HLA-II complexCTAG1B/HLA-II complex

Drugs targeting this complex function by facilitating the presentation of NY-ESO-1 peptides on HLA class II molecules of dendritic cells or by providing engineered T cells that recognize this specific peptide-MHC complex. Vaccines and viral vectors deliver the NY-ESO-1 antigen to dendritic cells, which then process and present it to endogenous CD4+ T cells [PMID: 24733525, PMID: 30635439]. Alternatively, TCR-T cell therapies utilize synthetic T-cell receptors designed to bind directly to the NY-ESO-1/HLA-II complex, triggering T cell activation, cytokine release, and the recruitment of other immune effectors to the tumor site [PMID: 27524443].